Caris Life Sciences, Inc.
CAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $7,131 | $7,131 | $7,134 | $503 |
| - Cash | $64 | $56 | $107 | $54 |
| + Debt | $424 | $217 | $271 | $1,746 |
| Enterprise Value | $7,491 | $7,291 | $7,298 | $2,195 |
| Revenue | $412 | $306 | $258 | $294 |
| % Growth | 34.7% | 18.4% | -12.1% | – |
| Gross Profit | $179 | $89 | $80 | $184 |
| % Margin | 43.4% | 29.2% | 31% | 62.6% |
| EBITDA | -$183 | -$261 | -$246 | $254 |
| % Margin | -44.4% | -85.2% | -95.1% | 86.5% |
| Net Income | -$282 | -$341 | -$321 | $28 |
| % Margin | -68.4% | -111.5% | -124.1% | 9.4% |
| EPS Diluted | -2.7 | -1.82 | -1.57 | 1.55 |
| % Growth | -48.4% | -15.9% | -201.3% | – |
| Operating Cash Flow | -$245 | -$276 | -$286 | $277 |
| Capital Expenditures | -$8 | -$22 | -$42 | -$219 |
| Free Cash Flow | -$254 | -$298 | -$328 | $58 |